Internal Medicine Doctors in Bolivia, NC Accepting Medicare

8 Internal Medicine doctors found. Showing 1 - 8

Dr. Timothy Michael Foeller, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 Hospital Dr Ne, Bolivia, NC 28422 Phone: 910-721-2070    Fax: 910-721-2074

William Joseph Faircloth, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 Hospital Dr Ne, Bolivia, NC 28422 Phone: 910-755-1004    Fax: 910-755-1474

Alan Joseph Bloszko Jr, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 Hospital Dr Ne, Bolivia, NC 28422 Phone: 910-721-2070    Fax: 910-721-2074

Dr. Roberta Samelson Bracken, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 25 Courthouse Dr Ne, Bolivia, NC 28422 Phone: 910-253-2250    Fax: 910-253-2370

Lawrence James Mason, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 Hospital Dr Ne, Bolivia, NC 28422 Phone: 910-721-2070    Fax: 910-755-1474

David John Koenig, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 Hospital Dr Ne, Bolivia, NC 28422 Phone: 910-721-2070    Fax: 910-721-2074

Patrick Christopher Ellis, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 584 Hospital Dr Ne, Bolivia, NC 28422 Phone: 910-662-9500    Fax: 910-668-9501

James Bruce Adams, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 Hospital Dr Ne, Bolivia, NC 28422 Phone: 910-755-1004    Fax: 910-755-1474

News Archive

Convergent Dental's Solea CO2 dental laser system receives FDA clearance

Convergent Dental, Inc., a privately held dental device and technology company, announced today that the U.S. Food and Drug Administration (FDA) has cleared Solea™ for ablation of hard tissue for caries removal and cavity preparation. Solea is the first CO2 laser technology system that has received FDA clearance for hard tissue indications.

FDA EMDAC schedules to review VIVUS' Qnexa NDA for treatment of obesity

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Qnexa for the treatment of obesity on February 22, 2012.

FDA stops pain drug trial over safety concerns

Johnson & Johnson revealed Tuesday this week that a clinical trial of its experimental pain drug, fulranumab, has been stopped after the Food and Drug Administration expressed concerns that patients taking the drug could suffer increased joint damage.

Researchers find that healthy, younger adults could be at risk for heart disease

Even younger adults who have few short-term risk factors for heart disease may have a higher risk of developing heart disease over their lifetimes, according to new findings by a UT Southwestern Medical Center researcher.

Read more Medical News

› Verified 1 days ago